Accès ouvert
2026
article
OpenAlex
Jeanny B. Aragon-Ching, Fumihiko Urabe, Shugo Yajima
The application of circulating tumor DNA (ctDNA) has advanced in the treatment of multiple cancer types, including urothelial cancer (UC). While ctDNA currently plays a limited role in non-muscle-invasive bladder cancer (NMIBC), its relevance is expanding in muscle-invasive bladder cancer (MIBC), as …
es, us, jp
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Eric Martin, Eun-mi Yu, Annika Murthi, Hongkun Wang et autres
Abstract Introduction: Circulating tumor DNA (ctDNA) enables minimally invasive monitoring of tumor biology and treatment response. Although ctDNA is increasingly used across malignancies, its utility in renal cell carcinoma (RCC) has not been well established. We sought to understand the relationship between …
us
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
Thomas Powles, Vadim S. Koshkin, Jonathan E. Rosenberg, Nobuaki Matsubara et autres
LBA631 Background: An estimated 60%-80% of patients (pts) with UC have HER2-expressing tumors. DV is an ADC comprising a novel anti-HER2 antibody, disitamab, and an MMAE payload. DV demonstrated promising antitumor activity and a manageable safety profile as monotherapy in Chinese pts …
gb, us, jp, au, il, ca
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
Melissa L. Abel, Esther Mena, Liza Lindenberg, Megan Hausler et autres
33 Background: Historically, PSA DT can be prognostic for metastasis free survival in BCR (as defined on computed tomography (CT) and bone scan). PSA DT is also an important tool in risk stratification in BCR to identify which patients (pts) require therapy …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Ravi Amrit Madan, Liza Lindenberg, Esther Mena, Jeanny B. Aragon-Ching et autres
23 Background: Enzalutamide (enza) monotherapy is a treatment option for BCR. Although EMBARK evaluated 9 months of enza monotherapy, a previous study (n=38) at the National Cancer Institute (NCI) evaluated two 3-month intermittent courses of enza without androgen deprivation (ADT). The results …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Anders Ullén, Christof Vulsteke, Jens Bedke, Steffen Rausch et autres
638 Background: The phase 3 KEYNOTE-905/EV-303 study (NCT03924895) showed significantly improved EFS, OS, and pCR rate with neoadj-adj EV + pembro added to radical cystectomy with pelvic lymph node dissection (RC + PLND) in pts with MIBC who were cisplatin-ineligible. We report …
se, be, de, us, kr, co, ua, il, ru, jp, gb
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Eun-mi Yu, Hongkun Wang, Jeanny B. Aragon-Ching
591 Background: We previously reported demographics, race, stage, treatment, and survival patterns in testicular cancer (TC) patients in the U.S. using the National Cancer Database (NCDB) data (Yu et al., JCO:43 (5): Abs 622). We now examine race in a multivariable model …
us
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
Antonio Cigliola, Nazli Dizman, Chiara Mercinelli, Yao Zhu et autres
453 Background: Malignancies arising in young adults often exhibit biological and clinical behaviors distinct from those in older patients (pts). Currently, little information is available regarding the prognostic impact of age in mnccRCC. This study aimed to compare survival outcomes by age …
it, us, cn, in, Maroc
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Aanika B. Warner, Melissa L. Abel, Susan F. Slovin, Xiao X. Wei et autres
170 Background: Androgen receptor (AR) targeting strategies have demonstrated clinical impact in high-risk BCR (e.g., PSA DT<6 months (mos)) but are associated with significant toxicities. Given the median age of BCR ≥70 years (yrs) and a low risk of death from prostate …
us
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
Melissa L. Abel, Fatima H. Karzai, Philip Martin Arlen, Clara Chen et autres
192 Background: BCR pts have a rising PSA after definitive surgery or radiation, but negative CT/Tc-99m bone scans. While ADT-based strategies are commonly used, they can be associated with life-altering toxicities. Radium-223 is an alpha-emitting radiopharmaceutical that accumulates in areas of high …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Ravi Amrit Madan, Esther Mena, Liza Lindenberg, Megan Hausler et autres
37 Background: The use of PSMA imaging is impacting the management of BCR, but it remains unclear if treatment escalation is required for PSMA+ BCR. While patients (pts) at the highest risk of death from prostate cancer (e.g. PSA Doubling Time (DT) …
us
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Laura Meili Linville, H. Wang, Jeanny B. Aragon-Ching
48 Background: The incidence of stage IV prostate cancer in the United States has risen over the past decade, possibly reflecting changes in PSA screening guidelines. Recent studies have also shown increasing implementation of active surveillance in the initial management of intermediate-risk …
us
(code pays fourni par la source)